Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Assets (2020 - 2026)

Cytek Biosciences filings provide 6 years of Non-Current Assets readings, the most recent being $69.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 32.51% to $69.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $388.6 million, a 4.56% decrease, with the full-year FY2025 number at $69.5 million, down 32.51% from a year prior.
  • Non-Current Assets hit $69.5 million in Q4 2025 for Cytek Biosciences, down from $106.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $110.5 million in Q2 2025 to a low of $3.9 million in Q2 2021.
  • Median Non-Current Assets over the past 5 years was $69.5 million (2025), compared with a mean of $56.7 million.
  • Biggest five-year swings in Non-Current Assets: surged 1138.08% in 2023 and later tumbled 32.51% in 2025.
  • Cytek Biosciences' Non-Current Assets stood at $5.9 million in 2021, then soared by 133.84% to $13.7 million in 2022, then skyrocketed by 648.41% to $102.4 million in 2023, then increased by 0.64% to $103.1 million in 2024, then tumbled by 32.51% to $69.5 million in 2025.
  • The last three reported values for Non-Current Assets were $69.5 million (Q4 2025), $106.4 million (Q3 2025), and $110.5 million (Q2 2025) per Business Quant data.